FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954482364> ?p ?o ?g. }

• W2954482364 abstract "Androgen receptor (AR) signaling plays an essential role in all stages of prostate cancer. Androgen-deprivation therapy is generally effective for advanced prostate cancer until progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Most CRPC continues to be driven by AR signaling. AR transcriptional activity requires a functional N-terminal domain (NTD). Transactivation of AR is mediated by ligand-independent activation by cross-talk with signal transduction pathways targeting the AR NTD, gain-of-function mutations in AR ligand-binding domain (LBD), or expression of truncated AR splice variants that lack LBD (e.g., AR-V7). The intrinsically disordered AR NTD is essential for its transcriptional activity. It harbors six putative binding sites for Pin1, a proline isomerase that regulates protein conformation at specific phosphorylated-Ser/Thr-Pro motifs. All-trans retinoic acid (ATRA) is a validated and potent Pin1 inhibitor. Since conformational changes within the AR NTD are required for transactivation, perturbation of its structure may be a promising approach to block its activity. The purpose of this study was to assess a therapy that combined ATRA with antagonists of AR NTD, ralaniten (EPI-002) and its analogues. We hypothesized that targeting Pin1 activity with ATRA would disrupt the AR NTD and enhance inhibition by EPI compounds which bind to Tau-5 in the NTD. Using reporter gene assays, proliferation assays, and cell cycle analysis by flow cytometry, we tested ATRA in isolation and in combination with EPI in androgen-sensitive (LNCaP) and androgen-independent (LN95) prostate cancer cell lines. We found that treatment with ATRA decreased the transcriptional activity of AR and androgen-induced expression of PSA. ATRA also attenuated the transcriptional activity of AR-V7 and androgen-independent growth of LN95 cells expressing both full-length AR and AR-V7. Co-immunoprecipitation studies confirmed interactions between Pin1 and specific regions of AR NTD. In combination, ATRA had synergistic interaction with EPI compounds and lowered the effective inhibitory concentrations for blocking AR transcriptional activity. Furthermore, combinations decreased cell cycle progression of LN95 cells through S-phase, leading to accumulation of cells in G1 and induction of senescence. These preclinical findings showed that ATRA enhanced the potency of AR NTD inhibitors and support a novel therapeutic strategy for CRPC. Future studies will determine the in vivo antitumor effect of ATRA in combination with EPI compounds on the growth of CRPC xenografts. Citation Format: Jacky K. Leung, Marianne D. Sadar. Combining all-trans retinoic acid therapy with androgen receptor N-terminal domain inhibitors for the treatment of castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1023." @default.
• W2954482364 created "2019-07-12" @default.
• W2954482364 creator A5019840569 @default.
• W2954482364 creator A5089406877 @default.
• W2954482364 date "2019-07-01" @default.
• W2954482364 modified "2023-09-27" @default.
• W2954482364 title "Abstract 1023: Combining all-trans retinoic acid therapy with androgen receptor N-terminal domain inhibitors for the treatment of castration-resistant prostate cancer" @default.
• W2954482364 doi "https://doi.org/10.1158/1538-7445.sabcs18-1023" @default.
• W2954482364 hasPublicationYear "2019" @default.
• W2954482364 type Work @default.
• W2954482364 sameAs 2954482364 @default.
• W2954482364 citedByCount "0" @default.
• W2954482364 crossrefType "proceedings-article" @default.
• W2954482364 hasAuthorship W2954482364A5019840569 @default.
• W2954482364 hasAuthorship W2954482364A5089406877 @default.
• W2954482364 hasConcept C104317684 @default.
• W2954482364 hasConcept C121608353 @default.
• W2954482364 hasConcept C126322002 @default.
• W2954482364 hasConcept C1292079 @default.
• W2954482364 hasConcept C134018914 @default.
• W2954482364 hasConcept C185592680 @default.
• W2954482364 hasConcept C2777899217 @default.
• W2954482364 hasConcept C2777911890 @default.
• W2954482364 hasConcept C2779723316 @default.
• W2954482364 hasConcept C2779881493 @default.
• W2954482364 hasConcept C2780192828 @default.
• W2954482364 hasConcept C2780962315 @default.
• W2954482364 hasConcept C502942594 @default.
• W2954482364 hasConcept C55493867 @default.
• W2954482364 hasConcept C61367390 @default.
• W2954482364 hasConcept C62478195 @default.
• W2954482364 hasConcept C71315377 @default.
• W2954482364 hasConcept C71924100 @default.
• W2954482364 hasConcept C86339819 @default.
• W2954482364 hasConcept C86803240 @default.
• W2954482364 hasConcept C95444343 @default.
• W2954482364 hasConceptScore W2954482364C104317684 @default.
• W2954482364 hasConceptScore W2954482364C121608353 @default.
• W2954482364 hasConceptScore W2954482364C126322002 @default.
• W2954482364 hasConceptScore W2954482364C1292079 @default.
• W2954482364 hasConceptScore W2954482364C134018914 @default.
• W2954482364 hasConceptScore W2954482364C185592680 @default.
• W2954482364 hasConceptScore W2954482364C2777899217 @default.
• W2954482364 hasConceptScore W2954482364C2777911890 @default.
• W2954482364 hasConceptScore W2954482364C2779723316 @default.
• W2954482364 hasConceptScore W2954482364C2779881493 @default.
• W2954482364 hasConceptScore W2954482364C2780192828 @default.
• W2954482364 hasConceptScore W2954482364C2780962315 @default.
• W2954482364 hasConceptScore W2954482364C502942594 @default.
• W2954482364 hasConceptScore W2954482364C55493867 @default.
• W2954482364 hasConceptScore W2954482364C61367390 @default.
• W2954482364 hasConceptScore W2954482364C62478195 @default.
• W2954482364 hasConceptScore W2954482364C71315377 @default.
• W2954482364 hasConceptScore W2954482364C71924100 @default.
• W2954482364 hasConceptScore W2954482364C86339819 @default.
• W2954482364 hasConceptScore W2954482364C86803240 @default.
• W2954482364 hasConceptScore W2954482364C95444343 @default.
• W2954482364 hasLocation W29544823641 @default.
• W2954482364 hasOpenAccess W2954482364 @default.
• W2954482364 hasPrimaryLocation W29544823641 @default.
• W2954482364 hasRelatedWork W2012067226 @default.
• W2954482364 hasRelatedWork W2014862652 @default.
• W2954482364 hasRelatedWork W2017839954 @default.
• W2954482364 hasRelatedWork W2055913188 @default.
• W2954482364 hasRelatedWork W2057090339 @default.
• W2954482364 hasRelatedWork W2166264553 @default.
• W2954482364 hasRelatedWork W2246031602 @default.
• W2954482364 hasRelatedWork W2319590495 @default.
• W2954482364 hasRelatedWork W2331913944 @default.
• W2954482364 hasRelatedWork W2345499901 @default.
• W2954482364 hasRelatedWork W2405966902 @default.
• W2954482364 hasRelatedWork W2463336448 @default.
• W2954482364 hasRelatedWork W2514715990 @default.
• W2954482364 hasRelatedWork W2565270005 @default.
• W2954482364 hasRelatedWork W2741925895 @default.
• W2954482364 hasRelatedWork W2899579039 @default.
• W2954482364 hasRelatedWork W3003527055 @default.
• W2954482364 hasRelatedWork W3142133875 @default.
• W2954482364 hasRelatedWork W3178882185 @default.
• W2954482364 hasRelatedWork W3179049066 @default.
• W2954482364 isParatext "false" @default.
• W2954482364 isRetracted "false" @default.
• W2954482364 magId "2954482364" @default.
• W2954482364 workType "article" @default.